| Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases … E Daudén, G Carretero, R Rivera, C Ferrándiz, M Llamas-Velasco, ... Journal of the American Academy of Dermatology 83 (1), 139-150, 2020 | 51 | 2020 |
| Cutaneous and mucocutaneous leishmaniasis: experience of a Mediterranean hospital M Garrido-Jareño, A Sahuquillo-Torralba, R Chouman-Arcas, ... Parasites & vectors 13, 1-7, 2020 | 45 | 2020 |
| Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis O Baniandrés-Rodríguez, J Vilar-Alejo, R Rivera, JM Carrascosa, ... Journal of the American Academy of Dermatology 84 (2), 513-517, 2021 | 33 | 2021 |
| Pembrolizumab: a new drug that can induce exacerbations of psoriasis A Sahuquillo-Torralba, R Ballester-Sánchez, C Pujol-Marco, ... Actas Dermo-Sifiliogr ficas (English Edition) 3 (107), 264-266, 2016 | 27 | 2016 |
| A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients JM Ortiz-Salvador, M Saneleuterio-Temporal, J Magdaleno-Tapial, ... Journal of the American Academy of Dermatology 81 (2), 427-432, 2019 | 26 | 2019 |
| Real‐world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group E Del Alcázar, JA Suárez‐Pérez, S Armesto, R Rivera, E Herrera‐Acosta, ... Journal of the European Academy of Dermatology and Venereology 34 (12), 2821 …, 2020 | 25 | 2020 |
| Effectiveness and safety of guselkumab for the treatment of psoriasis in real‐world settings at 24 weeks: a retrospective, observational, multicentre study by the Spanish … E Del Alcázar, A López‐Ferrer, Á Martínez‐Doménech, R Ruiz‐Villaverde, ... Dermatologic therapy 35 (2), e15231, 2022 | 24 | 2022 |
| Accuracy of SCORTEN and ABCD‐10 to predict mortality and the influence of renal function in Stevens–Johnson syndrome/toxic epidermal necrolysis I Torres‐Navarro, Á Briz‐Redón, G Botella‐Casas, A Sahuquillo‐Torralba, ... The Journal of Dermatology 47 (10), 1182-1186, 2020 | 18 | 2020 |
| Effect of sex in systemic psoriasis therapy: differences in prescription, effectiveness and safety in the BIOBADADERM prospective cohort CP Hernández-Fernández, G Carretero, R Rivera, C Ferrandiz, E Dauden, ... Acta Dermato-Venereologica 101 (1), 2021 | 16 | 2021 |
| Multicenter retrospective study of secukinumab drug survival in psoriasis patients in a daily practice setting: a long-term experience in Spain E Daudén, GPG de Lima, S Armesto, E Herrera-Acosta, D Vidal, ... Dermatology and Therapy 11, 2207-2215, 2021 | 11 | 2021 |
| MiR-138-5p suppresses cell growth and migration in melanoma by targeting telomerase reverse transcriptase E Tarazón, B de Unamuno Bustos, R Murria Estal, G Pérez Simó, ... Genes 12 (12), 1931, 2021 | 11 | 2021 |
| Women with moderate‐to‐severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age‐adjusted fertility rate when compared with the general population A Gonzalez‐Cantero, G Carretero, R Rivera, C Ferrándiz, E Daudén, ... British Journal of Dermatology 181 (5), 1085-1087, 2019 | 11 | 2019 |
| Complete response of a locally advanced basosquamous carcinoma with vismodegib treatment A Sahuquillo-Torralba, M Llavador-Ros, J Caballero-Daroqui, ... Indian Journal of Dermatology, Venereology and Leprology 85, 549, 2019 | 9 | 2019 |
| Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting A Reolid, S Armesto, A Sahuquillo-Torralba, T Torres, R Feltes, ... Journal of the American Academy of Dermatology 87 (3), 705-709, 2022 | 8 | 2022 |
| The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry M Munera-Campos, J Vilar-Alejo, R Rivera, JM Carrascosa, E Daudén, ... Journal of Dermatological Treatment 33 (4), 2110-2117, 2022 | 8 | 2022 |
| Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study. R Rivera, A Martorell, A López, L Salgado, A Sahuquillo, P Cueva, ... Journal of the European Academy of Dermatology & Venereology 35 (1), 2021 | 8 | 2021 |
| Pyoderma Gangrenosum With Ulcerative Colitis Successfully Treated With Ustekinumab. J Piqueras-García, AJ Sahuquillo-Torralba, I Torres-Navarro, ... Actas Dermo-sifiliograficas 110 (9), 776-778, 2019 | 7 | 2019 |
| Cambios en las tendencias de la prescripción y causas de la interrupción en los tratamientos biológicos indicados en la psoriasis durante los primeros 10 años. Datos obtenidos … DP Ruiz-Genao, G Carretero, R Rivera, C Ferrándiz, E Daudén, ... Actas Dermo-Sifiliográficas 111 (9), 752-760, 2020 | 6 | 2020 |
| Risk of hepatitis B virus reactivation in patients on secukinumab for psoriasis: a series of 4 cases LM Moneva-Leniz, A Sahuquillo-Torralba, A Vila-Payeras, ... Actas Dermo-Sifiliograficas 111 (7), 612-613, 2020 | 6 | 2020 |
| Sclerodermatous chronic graft-versus-host disease treated with imatinib: a dermatological perspective P Molés-Poveda, P Montesinos, J Sanz-Caballer, B de Unamuno, ... Actas Dermo-Sifiliográficas (English Edition) 109 (3), 241-247, 2018 | 6 | 2018 |
